Experience Sleepio, Daylight, and SparkRx firsthand

Learn why so many organizations choose Big Health to treat insomnia, anxiety, and depression in their populations.

Sleepio is a customized six-week program that teaches techniques based on cognitive behavioral therapy (CBT) principles to treat insomnia, such as progressive relaxation, thought-blocking, sleep restriction, and mindful observation.

Daylight is a tailored four-week program that teaches CBT techniques to treat anxiety. Applied relaxation, cognitive restructuring, stimulus control, and imaginal exposure help patients respond better to stress and overcome worry and anxiety.

SparkRx is the first evidence-based digital therapeutic for patients ages 13+ experiencing symptoms of depression. SparkRx is a five-week program that teaches CBT techniques like psychoeducation, mood tracking, activity scheduling, and more.

Ready to help millions back to good mental health?

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients who are followed by and diagnosed with depression by a medical provider, SparkRx can be made available as an adjunct to their usual medical care for depression. SparkRx does not replace the care of a medical provider or a patient’s medication. SparkRx has not been cleared by the U.S. Food and Drug Administration (FDA) for these indications.